Genetic engineering for haemophilia A.
At first sight, haemophilia A would appear to be an ideal candidate for treatment by gene therapy. There is a single gene defect; cells in different parts of the body, but especially the liver, produce Factor VIII, and only 5% of normal levels of Factor VIII are necessary to prevent the serious symptoms of bleeding. This review attempts to outline the status of gene therapy at present and efforts that have been made to overcome the difficulties and remaining problems that require solving. Undoubtedly, success will be achieved, but it is likely that considerably more work will be necessary before experimental models can be introduced into the clinic with any likelihood of success. The most successful results in animals that may have clinical application were from introducing the Factor VIII gene to newborn animals before antibodies are produced, presumably inducing a state of tolerance.
Gan
Shu Uin
SU
National University of Singapore, Department of Surgery, MD11, 04-08, 10 Medical Drive, 117597 Singapore. surgsu@nus.edu.sg
Kon
Oi Lian
OL
Calne
Roy Y
RY
D000818:Animals; D005818:Genetic Engineering / Q000379:methods* / Q000639:trends; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006467:Hemophilia A / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D006801:Humans